• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·002210.KS
Share

Dong Sung Bio Pharm.Co.,Ltd. Stocks

₩ 1269Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₩ 23.58M

₩ 1269
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dong Sung Bio Pharm.Co.,Ltd. is a South Korean company with diverse operations spanning pharmaceuticals, cosmetics, hair dye manufacturing, and photodynamic therapy. Its extensive product range includes a broad selection of over-the-counter (OTC) medications designed to treat a variety of conditions. These encompass liver ailments, menopausal symptoms, skin disorders, obesity, digestive and gum health issues, and hair loss. The company's OTC offerings also feature remedies for fever, pain, inflammation, respiratory illnesses, scar reduction, and sleep disturbances, along with antiviral, anti-diarrhea, anti-nausea, blood circulation enhancing, antifungal, and antihistamine drugs. Supplementary OTC products include keratin softeners, eye nutrition supplements, and essential vitamins. Furthermore, Dong Sung Bio Pharm produces ethical (prescription-only, or ETC) drugs. These target specific medical areas such as endocrine, gastrointestinal, circulatory, neuropsychological, and oncological conditions. Its ETC portfolio also contains analgesic and anti-inflammatory agents, dermato-urinary treatments, antiviral, antibiotic, antifungal, and antihistamine medications, as well as respiratory drugs, steroids, and ophthalmic drops. Beyond its pharmaceutical lines, the company offers a range of consumer health and personal care items. These include hair coloring products, functional health foods, medical devices, various daily necessities, muscle taping supplies, disinfectants, toothpastes, shampoos for anti-hair loss and hair growth, and sanitary pads. Dong Sung Bio Pharm.Co.,Ltd. was founded in 1957 and maintains its headquarters in Seoul, South Korea.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026